Company enterprise capital and biotechnology in 2025: challenges, alternatives, and threats

When biotechs begin fundraising they recurrently flip to the enterprise capital market looking for funding. The pool of VC cash might be giant, and a part of that pool is company enterprise capital. Backed by companies eager to determine the following huge factor in biotechnology, company VC cash might be a lovely method for biotechs to lift funds privately whereas benefiting from the help and experience of company supporters.

This week I talked with Paolo Di Giorgio and Regina Hodits of Angelini Ventures, the company VC arm of Angelini Industries, itself the mum or dad firm of Angelini Pharma. Paolo and Regina lay out their perspective on the present fundraising panorama, determine the traits and alternatives for revolutionary biotechs in Europe, and stroll me although the largest threats to the biotech funding market they see on the close to horizon.

01:15               Introducing Paolo Di Giorgio

04:00               Introducing Regine Hodits

05:31               The mission of Angelini Ventures

09:55               Focus areas and investments in early stage science

14:30               The state of enterprise capital funding in biotech in 2025

17:48               Why biotechs ought to favor company enterprise capital

20:43               Why networking and experience matter in fundraising

26:05               The therapeutic areas and modalities which are scorching proper now

29:19               Geographic focus for company enterprise capital

33:28               Threats on the horizon

36:36               What retains a company VC investor up at evening?

40:13               Keep up a correspondence with Angelini Ventures

Interested by being a sponsor of an episode of our podcast? Uncover how one can become involved right here! 

Keep up to date by subscribing to our e-newsletter